У женщин, принимающих противозачаточные таблетки, с избыточным весом в 12 раз повышен риск развития церебрального венозного тромбоза, а с ожирением - в 30 раз чаще, чем у женщин с нормальным весом:
Risk of Cerebral Venous Thrombosis in Obese Women [Ссылки могут видеть только зарегистрированные и активированные пользователи]
Summary
•High-dose combined oral contraception (>50 μg) is associated with higher risks of VTE than lower-dose formulations. (Grade B)
•Evidence is conflicting whether preparations of COC with 50 μg EE have a higher risk of thrombosis compared with sub-50 μg EE formulations, although several large studies have seen an increased risk of VTE in 50 μg EE COCs. (Grade B)
•There is no reliable evidence that EE doses lower than 35 μg have less VTE risk than 35 μg formulations. (Grade B)
•There is fair evidence that preparations of COCs with drospirenone or third-generation progestins have only a slightly higher risk of VTE compared with those containing norethindrone or levonorgestrel. (Grade B)
•There is insufficient evidence that the contraceptive patch or contraceptive vaginal ring has a different risk of VTE compared with COCs. (Grade C)
•There is fair evidence that tobacco use, age (>35 years), obesity, hypertension, and the presence of hereditary thrombophilias (including factor V Leiden mutation, prothrombin G20210A mutation and protein C, protein S, or antithrombin deficiency) increase the risk of thrombotic events in the setting of CHC use. (Grade B)
---
Combined hormonal contraception and the risk of venous thromboembolism: a guideline
[Ссылки могут видеть только зарегистрированные и активированные пользователи](16)62847-9/fulltext